New 13D23
New 13G55
Stated intents1
The week of 2025-09-15, 23 holders filed a new Schedule 13D and 55 a new Schedule 13G reporting 5% or more of a company, and 1 13D filing stated in Item 4 an intent to influence the company. Open a company for every holder and the purpose each 13D states, quoted.
New Schedule 13D
| Filed | Company | Holder | Percent | Filing |
|---|---|---|---|---|
| 2025-09-15 | Apollo Origination II (Levered) Capital Trust | Apollo Principal Holdings B GP, LLC | 100% | SCHEDULE 13D |
| 2025-09-16 | Franklin BSP Real Estate Debt BDC | Treasurer of the State of North Carolina | 99.9% | SCHEDULE 13D |
| 2025-09-16 | Maase Inc. | Dejun Yu | 41.95% | SCHEDULE 13D |
| 2025-09-18 | Panamera Holdings Corp | Rain Cage Carbon Inc. | 33.9% | SCHEDULE 13D |
| 2025-09-15 | Quantumsphere Acquisition Corp | Whiteowl Holdings LLC | 27.41% | SCHEDULE 13D |
| 2025-09-17 | Angel Studios, Inc. | Neal Harmon | 18.3% | SCHEDULE 13D |
| 2025-09-18 | Angel Studios, Inc. | Jeffrey Harmon | 18.2% | SCHEDULE 13D |
| 2025-09-16 | Strive, Inc. | Vivek Ramaswamy | 17.92% | SCHEDULE 13D |
| 2025-09-18 | Forward Industries, Inc. | Multicoin Capital Management, LLC | 15.7% | SCHEDULE 13D |
| 2025-09-19 | LB Pharmaceuticals Inc. | Deep Track Capital, LP | 14.9% | SCHEDULE 13D |
| 2025-09-18 | Forward Industries, Inc. | Galaxy Digital LP | 9.99% | SCHEDULE 13D |
| 2025-09-19 | Eightco Holdings Inc. | Mozayyx Ugp, LLC | 9.99% | SCHEDULE 13D |
| 2025-09-19 | Artelo Biosciences, Inc. | Farb Daniel Stuart intent stated | 9.8% | SCHEDULE 13D |
| 2025-09-18 | Forward Industries, Inc. | J Digital 6 Cayman Ltd. | 9.3% | SCHEDULE 13D |
| 2025-09-19 | dMY Squared Technology Group, Inc. | National Philanthropic Trust | 9% | SCHEDULE 13D |
| 2025-09-15 | Auburn National Bancorporation, Inc | Anne M. May | 8.3% | SCHEDULE 13D |
| 2025-09-15 | DENNY'S Corp | JCP Investment Management, LLC | 7.8% | SCHEDULE 13D |
| 2025-09-15 | Auburn National Bancorporation, Inc | Bruce Steven Spencer | 7.2% | SCHEDULE 13D |
| 2025-09-16 | Inflection Point Acquisition Corp. V | Inflection Point Fund I LP | 6.63% | SCHEDULE 13D |
| 2025-09-18 | StepStone Group Inc. | Jose A. Fernandez | 6% | SCHEDULE 13D |
| 2025-09-18 | CG Oncology, Inc. | Longitude Capital Partners IV, LLC | 6% | SCHEDULE 13D |
| 2025-09-19 | Mobix Labs | Keyvan Samini | 5.6% | SCHEDULE 13D |
| 2025-09-18 | StepStone Group Inc. | Thomas Keck | 5.2% | SCHEDULE 13D |
New Schedule 13G
| Filed | Company | Holder | Percent | Filing |
|---|---|---|---|---|
| 2025-09-16 | Bio Green Med Solution, Inc. | FITTERS Diversified Berhad | 19.99% | SCHEDULE 13G |
| 2025-09-17 | Angel Studios, Inc. | Stephen D. Oskoui | 19.64% | SCHEDULE 13G |
| 2025-09-16 | Camp4 Therapeutics Corporation | Coastlands Capital LP | 10% | SCHEDULE 13G |
| 2025-09-15 | X4 Pharmaceuticals, Inc. | Bain Capital Life Sciences Fund, L.P. | 9.99% | SCHEDULE 13G |
| 2025-09-17 | Silexion Therapeutics Corp | Mitchell P. Kopin | 9.99% | SCHEDULE 13G |
| 2025-09-18 | Soluna Holdings, Inc | Generate Strategic Credit Master Fund I-B, L.P. | 9.99% | SCHEDULE 13G |
| 2025-09-18 | Nexttrip, Inc. | Alumni Capital LP | 9.99% | SCHEDULE 13G |
| 2025-09-15 | Intercont (Cayman) Ltd | Streeterville Capital LLC | 9.9% | SCHEDULE 13G |
| 2025-09-15 | GCL Global Holdings, Ltd | ATW Interactive Ventures, LLC | 9.9% | SCHEDULE 13G |
| 2025-09-16 | Eightco Holdings Inc. | CoinFund Management LLC | 9.9% | SCHEDULE 13G |
| 2025-09-18 | Silexion Therapeutics Corp | Lind Global Fund III LP | 9.9% | SCHEDULE 13G |
| 2025-09-18 | Co-Diagnostics, Inc. | Orca Capital AG | 9.9% | SCHEDULE 13G |
| 2025-09-19 | Strive, Inc. | Jane Street Group, LLC | 9.9% | SCHEDULE 13G |
| 2025-09-15 | Rave Restaurant Group, Inc. | Bares Brian Timothy | 9.8% | SCHEDULE 13G |
| 2025-09-17 | Aptevo Therapeutics Inc. | Point72 Asset Management, L.P. | 9.1% | SCHEDULE 13G |
| 2025-09-17 | CoastalSouth Bancshares, Inc. | W. Kirk Wycoff | 8.87% | SCHEDULE 13G |
| 2025-09-15 | Gamehaus Holdings Inc. | Beijing Zhiyi Capital Investment Management Co., Ltd. | 8.68% | SCHEDULE 13G |
| 2025-09-16 | SuperX AI Technology Ltd | Yong Rong (HK) Asset Management Ltd | 8.3% | SCHEDULE 13G |
| 2025-09-16 | Talphera, Inc. | Lytton Laurence W | 8% | SCHEDULE 13G |
| 2025-09-16 | comScore, Inc. | Mount Logan Capital Inc. | 8% | SCHEDULE 13G |
| 2025-09-16 | Eightco Holdings Inc. | Discovery Capital Management, LLC | 7.9% | SCHEDULE 13G |
| 2025-09-18 | LB Pharmaceuticals Inc. | TCG Crossover GP II, LLC | 7.8% | SCHEDULE 13G |
| 2025-09-18 | Climb Bio, Inc. | Pontifax VI G.P. L.P. | 7.7% | SCHEDULE 13G |
| 2025-09-17 | Camp4 Therapeutics Corporation | Vivo Opportunity Fund Holdings, L.P. | 7.6% | SCHEDULE 13G |
| 2025-09-19 | BioCardia, Inc. | Lincoln Alternative Strategies LLC | 7.54% | SCHEDULE 13G |
| 2025-09-19 | Eightco Holdings Inc. | Bitmine Immersion Technologies, Inc. | 7.54% | SCHEDULE 13G |
| 2025-09-15 | Serve Robotics Inc | VK Services, LLC | 7.5% | SCHEDULE 13G |
| 2025-09-16 | Synchronoss Technologies, Inc. | Mount Logan Capital Inc. | 7.5% | SCHEDULE 13G |
| 2025-09-19 | LB Pharmaceuticals Inc. | RA Capital Management, L.P. | 7.5% | SCHEDULE 13G |
| 2025-09-19 | Liveperson Inc | Davidson Kempner Capital Management LP | 7% | SCHEDULE 13G |
| 2025-09-18 | Graftech International Ltd | Graphite India Ltd | 6.8% | SCHEDULE 13G |
| 2025-09-18 | Inflection Point Acquisition Corp. V | Linden Advisors LP | 6.7% | SCHEDULE 13G |
| 2025-09-19 | Vireo Growth Inc. | Roger Primm | 6.5% | SCHEDULE 13G |
| 2025-09-19 | MediWound Ltd. | HOLD Alapkezelo Zrt. | 6.5% | SCHEDULE 13G |
| 2025-09-15 | Silexion Therapeutics Corp | Orca Capital AG | 6.2% | SCHEDULE 13G |
| 2025-09-15 | Silexion Therapeutics Corp | Lincoln Alternative Strategies LLC | 6.18% | SCHEDULE 13G |
| 2025-09-17 | Domo, Inc. | Portolan Capital Management, LLC | 6.05% | SCHEDULE 13G |
| 2025-09-18 | Strive, Inc. | Millennium Management LLC | 6% | SCHEDULE 13G |
| 2025-09-19 | Traws Pharma, Inc. | Squadron Capital Management LLC | 6% | SCHEDULE 13G |
| 2025-09-18 | Talon Capital Corp. | Linden Advisors LP | 5.8% | SCHEDULE 13G |
| 2025-09-19 | BioCryst Pharmaceuticals, Inc. | Deerfield Mgmt, L.P. | 5.8% | SCHEDULE 13G |
| 2025-09-17 | Semler Scientific, Inc. | Capital Ventures International | 5.7% | SCHEDULE 13G |
| 2025-09-18 | Telomir Pharmaceuticals, Inc. | John Paul DeJoria, as trustee of the John Paul DeJoria Family Trust, and in his individual capacity | 5.5% | SCHEDULE 13G |
| 2025-09-18 | LB Pharmaceuticals Inc. | Commodore Capital LP | 5.5% | SCHEDULE 13G |
| 2025-09-17 | Bionano Genomics, Inc. | Lincoln Alternative Strategies LLC | 5.42% | SCHEDULE 13G |
| 2025-09-18 | Bionano Genomics, Inc. | Richard Abbe | 5.4% | SCHEDULE 13G |
| 2025-09-16 | Constellium Se | Millennium Management LLC | 5.3% | SCHEDULE 13G |
| 2025-09-16 | Terns Pharmaceuticals, Inc. | Commodore Capital LP | 5.3% | SCHEDULE 13G |
| 2025-09-18 | OTG Acquisition Corp. I | Linden Advisors LP | 5.3% | SCHEDULE 13G |
| 2025-09-19 | Beta Bionics, Inc. | Millennium Management LLC | 5.3% | SCHEDULE 13G |
| 2025-09-15 | GSR III Acquisition Corp. | Harraden Circle Investments, LLC | 5.26% | SCHEDULE 13G |
| 2025-09-17 | Asure Software Inc | Strong Richard S | 5.2% | SCHEDULE 13G |
| 2025-09-19 | Smart Sand, Inc. | Tontine Asset Associates, LLC | 5.1% | SCHEDULE 13G |
| 2025-09-15 | Armada Acquisition Corp. II | Harraden Circle Investments, LLC | 5.09% | SCHEDULE 13G |
| 2025-09-16 | Mesoblast Ltd | Gueck William J. | 5% | SCHEDULE 13G |
Stated intent
| Filed | Company | Holder | Percent | Filing |
|---|---|---|---|---|
| 2025-09-19 | Artelo Biosciences, Inc. | Farb Daniel Stuart intent stated | 9.8% | SCHEDULE 13D |
Download this data (CSV)79 rows, with sources
Tools for this story
Each opens in a new tab. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.